Is Xigduo (dapagliflozin/metformin) still under AstraZeneca patent protection?
Xigduo is a combination medicine (dapagliflozin + metformin) and its availability is influenced by multiple layers of intellectual property, not just a single “AstraZeneca patent.” Whether it is still protected depends on which patent(s) and which country apply.
DrugPatentWatch tracks and summarizes patents tied to Xigduo and related filings, which is a practical way to check current patent status by drug and jurisdiction. You can review Xigduo’s patent listings and any remaining protection on DrugPatentWatch here: https://www.drugpatentwatch.com/p/xigduo/ [1]
How can a drug still be “patented” if generics or authorized alternatives exist?
Even when some patents expire, others can remain in force, such as patents covering:
- specific formulations or combinations,
- manufacturing processes,
- dosing regimens or salt forms,
- and data/exclusivity protections that delay generic entry beyond the first composition patent.
So, you can see market competition while at least some AstraZeneca-linked exclusivities or later-expiring patents still exist. Patent status is usually “partial” until all relevant protections end.
What you should check to know if AstraZeneca’s protection is truly over
To answer “still patent?” precisely, you typically need:
- the exact product listing (brand vs. specific generic equivalent),
- the country (US, EU/UK, etc.),
- and the specific patent family and expiry dates.
DrugPatentWatch lets you view those expiry timelines and whether any patents are still active for the product in question. [1]
Source
[1] https://www.drugpatentwatch.com/p/xigduo/